文献速递认知障碍与痴呆帕金森病与运动障碍

帕金森病痴呆的诊室筛查:蒙特利尔帕金森病痴呆风险量表在4个纵向队列中的表现

Office-Based Screening for Dementia in Parkinson Disease: The Montreal Parkinson Risk of Dementia Scale in 4 Longitudinal Cohorts.
PubMed 文献 · JAMA Neurol · 2018-01-01

该多中心研究纳入4个帕金森病队列共607例基线无痴呆患者,前瞻性随访4.4年,评估蒙特利尔帕金森病痴呆风险量表的预测效度。量表8个条目均独立预测痴呆发生,总分>5分的高危组年转化率为14.9%,评分≥4分时灵敏度77.1%、特异度87.2%,曲线下面积0.877。

要点

  • 量表8个条目均独立预测痴呆发生(5%显著性水平)。
  • 高危组(>5分)年转化率14.9%,中危组(4-5分)5.8%,低危组(0-3分)0.6%。
  • 评分≥4分时灵敏度77.1%、特异度87.2%,曲线下面积0.877。

核心结论

  • 蒙特利尔帕金森病痴呆风险量表虽简单,但其预测效度等于或优于既往使用生物标志物评估的算法。
  • 作者认为未来值得进行头对头比较或对权重进行细化的研究。

研究设计与样本

  • 多中心研究,使用4个帕金森病队列(加拿大蒙特利尔、日本鸟取和帕金森病进展标志物计划站点),前瞻性随访4.4年。
  • 2005年5月至2016年6月共招募717例帕金森病患者,其中607例基线无痴呆且随访1年或以上者纳入分析。
  • 计算各基线量表变量与最终痴呆风险的关联,随机拆分队列以研究权重并确定最佳截断点,计算受试者工作特征曲线并分析其与选定生物标志物的相关性。

主要发现

  • 607例患者(平均[标准差]年龄63.4[10.1]岁;376例男性[62%])中,70例(11.5%)转化为痴呆。
  • 高危组(评分>5分)年转化率为14.9%,中危组(评分4-5分)为5.8%,低危组(评分0-3分)为0.6%。
  • 权重处理未带来显著优势。
  • 在所有队列中,总体预测效度的受试者工作特征曲线下面积为0.877(95%CI,0.829-0.924)。
  • 截断值≥4分时,灵敏度为77.1%(95%CI,65.6-86.3),特异度为87.2%(95%CI,84.1-89.9),阳性预测值(随访4.4年时)为43.90%(95%CI,37.76-50.24),阴性预测值为96.70%(95%CI,95.01-97.85)。

关键数值与推荐

  • 痴呆定义采用国际运动障碍学会一级标准。
  • 蒙特利尔帕金森病痴呆风险量表包含8个简单评估的条目。
  • 高危组评分为>5分,中危组为4-5分,低危组为0-3分。
  • 最佳截断值为≥4分。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Parkinson disease dementia dramatically increases mortality rates, patient expenditures, hospitalization risk, and caregiver burden. Currently, predicting Parkinson disease dementia risk is difficult, particularly in an office-based setting, without extensive biomarker testing. OBJECTIVE: To appraise the predictive validity of the Montreal Parkinson Risk of Dementia Scale, an office-based screening tool consisting of 8 items that are simply assessed. DESIGN, SETTING, AND PARTICIPANTS: This multicenter study (Montreal, Canada; Tottori, Japan; and Parkinson Progression Markers Initiative sites) used 4 diverse Parkinson disease cohorts with a prospective 4.4-year follow-up. A total of 717 patients with Parkinson disease were recruited between May 2005 and June 2016. Of these, 607 were dementia-free at baseline and followed-up for 1 year or more and so were included. The association of individual baseline scale variables with eventual dementia risk was calculated. Participants were then randomly split into cohorts to investigate weighting and determine the scale's optimal cutoff point. Receiver operating characteristic curves were calculated and correlations with selected biomarkers were investigated. MAIN OUTCOMES AND MEASURES: Dementia, as defined by Movement Disorder Society level I criteria. RESULTS: Of the 607 patients (mean [SD] age, 63.4 [10.1]; 376 men [62%]), 70 (11.5%) converted to dementia. All 8 items of the Montreal Parkinson Risk of Dementia Scale independently predicted dementia development at the 5% significance level. The annual conversion rate to dementia in the high-risk group (score, >5) was 14.9% compared with 5.8% in the intermediate group (score, 4-5) and 0.6% in the low-risk group (score, 0-3). The weighting procedure conferred no significant advantage. Overall predictive validity by the area under the receiver operating characteristic curve was 0.877 (95% CI, 0.829-0.924) across all cohorts. A cutoff of 4 or greater yielded a sensitivity of 77.1% (95% CI, 65.6-86.3) and a specificity of 87.2% (95% CI, 84.1-89.9), with a positive predictive value (as of 4.4 years) of 43.90% (95% CI, 37.76-50.24) and a negative predictive value of 96.70% (95% CI, 95.01-97.85). Positive and negative likelihood ratios were 5.94 (95% CI, 4.08-8.65) and 0.26 (95% CI, 0.17-0.40), respectively. Scale results correlated with markers of Alzheimer pathology and neuropsychological test results. CONCLUSIONS AND RELEVANCE: Despite its simplicity, the Montreal Parkinson Risk of Dementia Scale demonstrated predictive validity equal or greater to previously described algorithms using biomarker assessments. Future studies using head-to-head comparisons or refinement of weighting would be of interest.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Dawson BK, Fereshtehnejad SM, Anang JBM, et al. Office-Based Screening for Dementia in Parkinson Disease: The Montreal Parkinson Risk of Dementia Scale in 4 Longitudinal Cohorts. JAMA Neurol. 2018. PMID: 29582054. doi:10.1001/jamaneurol.2018.0254

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。